LTR Pharma has been featured in The Australian,  for our innovative breakthrough in men’s health – erectile dysfunction nasal spray, Spontan. In the article, non-exective

Australian Associated Press journalist Derek Rose has shared LTR Pharma’s story following the launch of our IPO last week. Of the Company’s commercialisation plans, he

LTR Pharma has been featured in Biotech Daily. The article discusses the potential for the Company to disrupt the Erectile Dysfunction (ED) market with its

LTR Pharma Executive Chairman, Lee Rodne, speaks to OnMarket about the Company’s Initial Public Offer (IPO) for a proposed listing on the Australian Securities Exchange

Australian Innovators Pursue $3.6Bn Erectile Dysfunction (ED) Market Brisbane-based LTR Pharma has today secured Ethics Approval for a bio-equivalence1 clinical study of its intranasal spray